Connecticut 2026 Session Status: Passed House 8 D cosponsors

HB 5225 — AN ACT PROHIBITING CERTAIN LICENSEES AND REGISTRANTS FROM SELLING, DISPENSING, TRANSFERRING OR DELIVERING ANY DRUG OR DEVICE TO EXECUTE A COURT-IMPOSED SENTENCE OF DEATH.

Last action — SENATE CALENDAR NUMBER 448

  1. ✓
    Introduced
  2. ✓
    In Committee
  3. 3
    Passed House
  4. 4
    Passed Senate
  5. 5
    To Executive
  6. 6
    Enacted

This bill has passed the House. Introduced February 18, 2026. It now moves to the second chamber.

Next likely step: consideration and a floor vote in the Senate.

Prognosis

Advancing 38% · moderate confidence

Where this bill stands today.

Odds of enactment

Moderate

How often bills like it became law.

  • Passed House

    Current position in the legislative process.

  • 8 sponsors

    8 primary, 0 co-sponsors signed on.

  • Single-party support

    Sponsorship is currently within one party (8 D).

Prognosis reads this bill's own signals — stage, sponsorship breadth, committee status, recorded votes and cross-state momentum. Odds come from a model trained on which bills have become law.

Bill Text

What changed in the latest version

46 added · 194 removed

Plain-language change summary

The updated version of Bill HB 5225 modifies certain terms related to the roles of wholesalers and manufacturers in the healthcare system. Specifically, it removes the mention of wholesalers and distributors and focuses solely on manufacturers and hospitals. This change matters because it simplifies the bill's focus, potentially streamlining regulations and clarifying the responsibilities of those directly involved in the supply chain for medical products.

→
Previous
Latest
House of Representatives General Assembly File No.
General Assembly Substitute Bill No.
186 February Session, 2026 Substitute House Bill No.
5225 February Session, 2026 AN ACT PROHIBITING CERTAIN LICENSEES AND REGISTRANTS FROM SELLING, DISPENSING, TRANSFERRING OR DELIVERING ANY DRUG OR DEVICE TO EXECUTE A COURT-IMPOSED SENTENCE OF DEATH.
5225 House of Representatives, March 26, 2026 The Committee onGeneralLawreportedthrough REP.LEMAR of the 96th Dist., Chairperson of the Committee on the part of the House, that the substitute bill ought to pass.
AN ACT PROHIBITING CERTAIN LICENSEES AND REGISTRANTS FROM SELLING, DISPENSING, TRANSFERRING OR DELIVERING ANY DRUG OR DEVICE TO EXECUTE A COURT-IMPOSED SENTENCE OF DEATH.
[(1) "Drugs", "devices" and "cosmetics" have the same meanings as defined in section 21a-92, "wholesaler" or "distributor" means a person, including, but not limited to, a medical device and oxygen provider, a third-party logistics provider, a virtual manufacturer or a virtual wholesale distributor, as such terms are defined in section 20-571, whether within or without the boundaries of the state of Connecticut, who supplies drugs, devices or cosmetics prepared, produced or packaged by manufacturers, to other wholesalers, manufacturers, distributors, hospitals, prescribing sHB5225 / File No.
[(1) "Drugs", "devices" and "cosmetics" have the same meanings as defined in section 21a-92, "wholesaler" or "distributor" means a person, including, but not limited to, a medical device and oxygen provider, a third-party logistics provider, a virtual manufacturer or a virtual wholesale distributor, as such terms are defined in section 20-571, whether within or without the boundaries of the state of Connecticut, who supplies drugs, devices or cosmetics prepared, produced or packaged by manufacturers, to other wholesalers, manufacturers, distributors,hospitals, prescribing practitioners, as defined in section 20-571, pharmacies, federal, state or municipal agencies, clinics or any other person as permitted under subsection (h) of this section, except that:
186 1 sHB5225 File No.
(A) A retail pharmacy or a pharmacy within a licensed hospital that supplies to another such pharmacy a quantity of a noncontrolled drug or a schedule II, III, IV or LCO 1 of 20 Substitute Bill No.
186 practitioners, as defined in section 20-571, pharmacies, federal, state or municipal agencies, clinics or any other person as permitted under subsection (h) of this section, except that:
5225 V controlled substance normally stocked by such pharmacies to provide for the immediate needs of a patient pursuant to a prescription or medication order of an authorized practitioner, (B) a pharmacy within a licensed hospital that supplies drugs to another hospital or an authorizedpractitionerfor researchpurposes, (C)aretailpharmacy that supplies a limited quantity of a noncontrolled drug or of a schedule II, III, IV or V controlled substance for emergency stock to a practitioner who is a medical director of a chronic and convalescent nursing home, of a rest home with nursing supervision, of a hospice inpatient facility licensed pursuant to section 19a-491 or of a state correctional institution, and (D) a pharmacy within a licensed hospital that contains another hospital wholly within such licensed hospital's physical structure that supplies to such contained hospital a quantity of a noncontrolled drug or a schedule II, III, IV, or V controlled substance normally stocked by such hospitals to provide for the needs of a patient, pursuant to a prescriptionormedicationorderofanauthorizedpractitioner,receiving inpatient care on a unit that is operated by the contained hospital, or receiving outpatient care in a setting operated by the contained hospital and such drug or substance is administered on-site by the contained hospital, shall not be deemed a wholesaler under this section;
(A) A retail pharmacy or a pharmacy within a licensed hospital that supplies to another such pharmacy a quantity of a noncontrolled drug or a schedule II, III, IV or V controlled substance normally stocked by such pharmacies to provide for the immediate needs of a patient pursuant to a prescription or medication order of an authorized practitioner, (B) a pharmacy within a licensed hospital that supplies drugs to another hospital or an authorizedpractitionerfor researchpurposes, (C)aretailpharmacy that supplies a limited quantity of a noncontrolled drug or of a schedule II, III, IV or V controlled substance for emergency stock to a practitioner who is a medical director of a chronic and convalescent nursing home, of a rest home with nursing supervision, of a hospice inpatient facility licensed pursuant to section 19a-491 or of a state correctional institution, and (D) a pharmacy within a licensed hospital that contains another hospital wholly within such licensed hospital's physical structure that supplies to such contained hospital a quantity of a noncontrolled drug or a schedule II, III, IV, or V controlled substance normally stocked by such hospitals to provide for the needs of a patient, pursuant to a prescriptionormedicationorderofanauthorizedpractitioner,receiving inpatient care on a unit that is operated by the contained hospital, or receiving outpatient care in a setting operated by the contained hospital and such drug or substance is administered on-site by the contained hospital, shall not be deemed a wholesaler under this section;
(2) "manufacturer" means (A) a person, whether within or without the boundaries of the state of Connecticut, who produces, prepares, cultivates, grows, propagates, compounds, converts or processes, directly or indirectly, by extraction from substances of natural origin or by means of chemical synthesis or by a combination of extraction and chemical synthesis, or who packages, repackages, labels or relabels a container under such manufacturer's own or any other trademark or label any drug, device or cosmetic for the purpose of selling such items, or (B) a sterile compounding pharmacy, as defined in section 20-633b, that dispenses sterile pharmaceuticals without a prescription or a patient-specific medical order;
(2) "manufacturer" means (A) a person, whether within or without the boundaries of the state of Connecticut, who produces, prepares, cultivates, grows, propagates, compounds, converts or processes, directly or indirectly, by extraction from substances of natural origin or by means of chemical synthesis or by a combination of extraction and chemical synthesis, or who packages, repackages, labels or relabels a container under such manufacturer's own or any other trademark or label any drug, device or cosmetic for the purpose of selling such items, or (B) a sterile compounding pharmacy, as defined in section 20-633b, that dispenses sterile pharmaceuticals without a prescription or a sHB5225 / File No.
186 2 sHB5225 File No.
186 patient-specific medical order;
and (4) "commissioner" means the Commissioner of Consumer Protection or the commissioner's designee.] (1) "Commissioner" means the Commissioner of Consumer Protection;
and (4) "commissioner" means the Commissioner of Consumer Protection or the commissioner's designee.] LCO 2 of 20 Substitute Bill No.
5225 (1) "Commissioner" means the Commissioner of Consumer Protection;
(4) "Distributor" or "wholesaler" (A) means a person, including, but not limited to, a medical device and oxygen provider, a third-party logistics provider, a virtual manufacturer or a virtual wholesale distributor, as such terms are defined in section 20-571, whether within or without the boundaries of the state of Connecticut, who supplies drugs, devices or cosmetics prepared, produced or packaged by manufacturers to other wholesalers, manufacturers, distributors, hospitals, prescribing practitioners, as defined in section 20-571, pharmacies, federal, state or municipal agencies, clinics or any other person as permitted under subsection (i) of this section, and (B) does not include (i) a retail pharmacy or a pharmacy within a licensed hospital that supplies to another such pharmacy a quantity of a noncontrolled drug or a schedule II, III, IV or V controlled substance normally stocked by such pharmacies to provide for the immediate needs of a patient pursuant to a prescription or medication order of an authorized practitioner, (ii) a pharmacy within a licensed hospital that supplies drugs to another hospital or an authorized practitioner for research purposes, (iii) a retail pharmacy that supplies a limited quantity of a noncontrolled drug or of a schedule II, III, IV or V controlled substance for emergency stock to a practitioner who is a medical director of (I) a chronic and convalescent nursing home, (II) a rest home with nursing supervision, (III) a hospice inpatient facility licensed pursuant to section 19a-491, or (IV) a correctional institution unless the correctional institution has actual knowledge that the noncontrolled drug or controlledsubstancewillbeusedtoexecuteasentenceofdeathimposed sHB5225 / File No.
(4) "Distributor" or "wholesaler" (A) means a person, including, but not limited to, a medical device and oxygen provider, a third-party logistics provider, a virtual manufacturer or a virtual wholesale distributor, as such terms are defined in section 20-571, whether within or without the boundaries of the state of Connecticut, who supplies drugs, devices or cosmetics prepared, produced or packaged by manufacturers to other wholesalers, manufacturers, distributors, hospitals, prescribing practitioners, as defined in section 20-571, pharmacies, federal, state or municipal agencies, clinics or any other person as permitted under subsection (i) of this section, and (B) does not include (i) a retail pharmacy or a pharmacy within a licensed hospital that supplies to another such pharmacy a quantity of a noncontrolled drug or a schedule II, III, IV or V controlled substance normally stocked by such pharmacies to provide for the immediate needs of a patient pursuant to a prescription or medication order of an authorized practitioner, (ii) a pharmacy within a licensed hospital that supplies drugs to another hospital or an authorized practitioner for research purposes, (iii) a retail pharmacy that supplies a limited quantity of a noncontrolled drug or of a schedule II, III, IV or V controlled substance for emergency stock to a practitioner who is a medical director of (I) a chronic and convalescent nursing home, (II) a rest home with nursing supervision, (III) a hospice inpatient facility licensed pursuant to section 19a-491, or (IV) a correctional institution unless the correctional institution has actual knowledge that the noncontrolled drug or controlledsubstancewillbeusedtoexecuteasentenceofdeathimposed by a court, and (iv) a pharmacy within a licensed hospital that contains another hospital wholly within such licensed hospital's physical structure that supplies to such contained hospital a quantity of a noncontrolled drug or a schedule II, III, IV or V controlled substance LCO 3 of 20 Substitute Bill No.
186 3 sHB5225 File No.
5225 normally stocked by such hospitals to provide for the needs of a patient, pursuant to a prescription or medication order of an authorized practitioner, receiving inpatient care on a unit that is operated by the contained hospital, or receiving outpatient care in a setting operated by the contained hospital and such drug or substance is administered on- site by the contained hospital;
186 by a court, and (iv) a pharmacy within a licensed hospital that contains another hospital wholly within such licensed hospital's physical structure that supplies to such contained hospital a quantity of a noncontrolled drug or a schedule II, III, IV or V controlled substance normally stocked by such hospitals to provide for the needs of a patient, pursuant to a prescription or medication order of an authorized practitioner, receiving inpatient care on a unit that is operated by the contained hospital, or receiving outpatient care in a setting operated by the contained hospital and such drug or substance is administered on- site by the contained hospital;
A fee of one hundred sHB5225 / File No.
A fee of one hundred ninety dollars shall be charged for each wholesaler's certificate and renewalthereof.
186 4 sHB5225 File No.
A separate certificate andcorresponding feeisrequired for each location existing in this state and for each location existing LCO 4 of 20 Substitute Bill No.
186 ninety dollars shall be charged for each wholesaler's certificate and renewalthereof.
5225 outside of this state that distributes products into this state.
A separate certificate andcorresponding feeisrequired for each location existing in this state and for each location existing outside of this state that distributes products into this state.
sHB5225 / File No.
(4) The furnishing by the applicant of false or fraudulent material in any application made in connection with drug manufacturing or distribution;
186 5 sHB5225 File No.
LCO 5 of 20 Substitute Bill No.
186 (4) The furnishing by the applicant of false or fraudulent material in any application made in connection with drug manufacturing or distribution;
5225 (5) Suspension, revocation or other sanction by federal, state or local government of any license or registration currently or previously held by the applicant for the manufacture or distribution of any drugs;
(5) Suspension, revocation or other sanction by federal, state or local government of any license or registration currently or previously held by the applicant for the manufacture or distribution of any drugs;
(2) Any criminal conviction of the registrant under any federal or sHB5225 / File No.
(2) Any criminal conviction of the registrant under any federal or state statute concerning drugs;
186 6 sHB5225 File No.
(3) The suspension, revocation or other restriction or penalty issued LCO 6 of 20 Substitute Bill No.
186 state statute concerning drugs;
5225 against a license or registration related to drugs;
(3) The suspension, revocation or other restriction or penalty issued against a license or registration related to drugs;
[(e Wholesalers and manufacturers] (f) Manufacturers and wholesalers shall operate in compliance with applicable federal, state and local statutes, regulations and ordinances, including any applicable laws concerning controlled substances, drug product salvaging or reprocessing.
[(e)] (f) [Wholesalers and manufacturers] Manufacturers and wholesalers shall operate in compliance with applicable federal, state and local statutes, regulations and ordinances, including any applicable laws concerning controlled substances, drug product salvaging or reprocessing.
sHB5225 / File No.
[(g)] (h) Before denying, suspending, revoking or refusing to renew a registration, or before issuing a letter of reprimand or placing a LCO 7 of 20 Substitute Bill No.
186 7 sHB5225 File No.
5225 registrant on probationary status, the commissioner shall afford the applicant or registrant an opportunity for a hearing in accordance with the provisions of chapter 54.
186 [(g)] (h) Before denying, suspending, revoking or refusing to renew a registration, or before issuing a letter of reprimand or placing a registrant on probationary status, the commissioner shall afford the applicant or registrant an opportunity for a hearing in accordance with the provisions of chapter 54.
Each registered manufacturer or wholesaler of drugs shall also send the Drug Control Division a copy of any suspicious orders submitted to the federal Drug Enforcement sHB5225 / File No.
Each registered manufacturer or wholesaler of drugs shall also send the Drug Control Division a copy of any suspicious orders submitted to the federal Drug Enforcement Administration pursuant to 21 CFR 1301.74.
186 8 sHB5225 File No.
LCO 8 of 20 Substitute Bill No.
186 Administration pursuant to 21 CFR 1301.74.
5225 (2) Each registered manufacturer or wholesaler of drugs that, based on concerns of potential diversion, ceases or declines distribution of any schedule II, III, IV or V controlled substance to a pharmacy, as defined in section 20-594, or to a practitioner, as defined in section 21a-316, in the state of Connecticut shall report the name of the pharmacy or practitioner, locationofthepharmacy or practitioner andthereasonsfor ceasing or declining distribution of such controlled substance in writing to the Director of the Drug Control Division, or to an electronic system designated by the Drug Control Division, not later than five business daysafter ceasing or declining distributionofsuchcontrolledsubstance.
(2) Each registered manufacturer or wholesaler of drugs that, based on concerns of potential diversion, ceases or declines distribution of any schedule II, III, IV or V controlled substance to a pharmacy, as defined in section 20-594, or to a practitioner, as defined in section 21a-316, in the state of Connecticut shall report the name of the pharmacy or practitioner, locationofthepharmacy or practitioner andthereasonsfor ceasing or declining distribution of such controlled substance in writing to the Director of the Drug Control Division, or to an electronic system designated by the Drug Control Division, not later than five business daysafter ceasing or declining distributionofsuchcontrolledsubstance.
sHB5225 / File No.
(a) (1) A licensed manufacturer or wholesaler may sell and dispense LCO 9 of 20 Substitute Bill No.
186 9 sHB5225 File No.
5225 controlled drugs to any of the following-named persons, but in the case of schedule II drugs only on an official written order or electronically through the Drug Enforcement Agency's Controlled Substance OrderingSystem:
186 (a) (1) A licensed manufacturer or wholesaler may sell and dispense controlled drugs to any of the following-named persons, but in the case of schedule II drugs only on an official written order or electronically through the Drug Enforcement Agency's Controlled Substance OrderingSystem:
sHB5225 / File No.
LCO 10 of 20 Substitute Bill No.
Show all 129 changed rows (89 more)
Previous
Latest
186 10 sHB5225 File No.
5225 [(e)] (d) Possession or control of controlled drugs obtained as authorized by this section shall be lawful only if obtained in the regular course of the business, occupation, profession, employment or duty of the possessor.
186 [(e)] (d) Possession or control of controlled drugs obtained as authorized by this section shall be lawful only if obtained in the regular course of the business, occupation, profession, employment or duty of the possessor.
(a) The commission may refuse to authorize the issuance of a temporary permit to practice pharmacy, may refuse to authorize the issuance or renewal of a license to practice pharmacy, a license to operate a pharmacy or a registration of a pharmacy intern or pharmacy technician, and may revoke, suspend or place conditions on a license or temporarypermittopracticepharmacy,alicensetooperateapharmacy, or a registration of a pharmacy intern or a pharmacy technician, and may assess a civil penalty of up to one thousand dollars per violation of any provision of this chapter or take other action permitted in subdivision (7) of section 21a-7 if the applicant or holder of the license, temporary permit or registration:(1)Hasviolatedastatute orregulation relating to drugs, devices or the practice of pharmacy of this state, any sHB5225 / File No.
(a) The commission may refuse to authorize the issuance of a temporary permit to practice pharmacy, may refuse to authorize the issuance or renewal of a license to practice pharmacy, a license to operate a pharmacy or a registration of a pharmacy intern or pharmacy technician, and may revoke, suspend or place conditions on a license or temporarypermittopracticepharmacy,alicensetooperateapharmacy, or a registration of a pharmacy intern or a pharmacy technician, and may assess a civil penalty of up to one thousand dollars per violation of any provision of this chapter or take other action permitted in subdivision (7) of section 21a-7 if the applicant or holder of the license, temporary permit or registration:(1)Hasviolatedastatute orregulation LCO 11 of 20 Substitute Bill No.
186 11 sHB5225 File No.
5225 relating to drugs, devices or the practice of pharmacy of this state, any state oftheUnitedStates,theUnitedStates,theDistrict ofColumbia, the Commonwealth of Puerto Rico, any territory or insular possession subject to the jurisdiction of the United States or a foreign jurisdiction;
186 state oftheUnitedStates,theUnitedStates,theDistrict ofColumbia, the Commonwealth of Puerto Rico, any territory or insular possession subject to the jurisdiction of the United States or a foreign jurisdiction;
(12) has split fees for professional services, including a discount or rebate, with a sHB5225 / File No.
(12) has split LCO 12 of 20 Substitute Bill No.
186 12 sHB5225 File No.
5225 fees for professional services, including a discount or rebate, with a prescribingpractitioneroranadministratororownerofanursinghome, hospital or other health care facility;
186 prescribingpractitioneroranadministratororownerofanursinghome, hospital or other health care facility;
(c) The commission shall not grant a renewal license to an applicant who (1) has not held a license authorized by the commission within five sHB5225 / File No.
(c) The commission shall not grant a renewal license to an applicant LCO 13 of 20 Substitute Bill No.
186 13 sHB5225 File No.
5225 who (1) has not held a license authorized by the commission within five years of the date of application unless the applicant has passed an examination satisfactory to the commission and has paid the fee required in section 20-601, or (2) within the calendar year preceding the date of application, dispensed or distributed a drug or device directly to another person with actual knowledge that such other person intended to use the drug or device to execute a sentence of death imposed by a court.
186 years of the date of application unless the applicant has passed an examination satisfactory to the commission and has paid the fee required in section 20-601, or (2) within the calendar year preceding the date of application, dispensed or distributed a drug or device directly to another person with actual knowledge that such other person intended to use the drug or device to execute a sentence of death imposed by a court.
(c) Any request for a controlled substance to execute a sentence of death imposed by a court shall be considered to be issued outside the sHB5225 / File No.
(c) Any request for a controlled substance to execute a sentence of LCO 14 of 20 Substitute Bill No.
186 14 sHB5225 File No.
5225 death imposed by a court shall be considered to be issued outside the context of a valid practitioner-patient relationship and not be a valid prescription.
186 context of a valid practitioner-patient relationship and not be a valid prescription.
(d) (1) A sterile compounding pharmacy may only provide patient- sHB5225 / File No.
LCO 15 of 20 Substitute Bill No.
186 15 sHB5225 File No.
5225 (d) (1) A sterile compounding pharmacy may only provide patient- specific sterile pharmaceuticals to patients, to practitioners of medicine, osteopathy, podiatry, dentistry or veterinary medicine, or to an acute care or long-term care hospital or health care facility licensed by the Department of Public Health.
186 specific sterile pharmaceuticals to patients, to practitioners of medicine, osteopathy, podiatry, dentistry or veterinary medicine, or to an acute care or long-term care hospital or health care facility licensed by the Department of Public Health.
If a sterile compounding pharmacy makes an emergency repair, the sterile compounding pharmacy shall sHB5225 / File No.
If a sterile compounding pharmacy LCO 16 of 20 Substitute Bill No.
186 16 sHB5225 File No.
5225 makes an emergency repair, the sterile compounding pharmacy shall notify the department of such emergency repair, in writing, not later than twenty-four hours after such repair is commenced.
186 notify the department of such emergency repair, in writing, not later than twenty-four hours after such repair is commenced.
The policy and procedure manual shall comply with the USP chapters.
The policy and procedure manual shall LCO 17 of 20 Substitute Bill No.
sHB5225 / File No.
5225 comply with the USP chapters.
186 17 sHB5225 File No.
(i) Each sterile compounding pharmacy shall report to the Department of Consumer Protection any administrative or legal action commenced against such sterile compounding pharmacy by any state or federal regulatory agency or accreditation entity not later than five business days after receiving notice of the commencement of such action.
186 (i) Each sterile compounding pharmacy shall report to the Department of Consumer Protection any administrative or legal action commenced against such sterile compounding pharmacy by any state or federal regulatory agency or accreditation entity not later than five business days after receiving notice of the commencement of such action.
(k) A practitioner, as specified in subdivision (1) of subsection (d) of this section, a hospital or a health care facility that receives sterile sHB5225 / File No.
LCO 18 of 20 Substitute Bill No.
186 18 sHB5225 File No.
5225 (k) A practitioner, as specified in subdivision (1) of subsection (d) of this section, a hospital or a health care facility that receives sterile pharmaceuticals shall report any errors related to such dispensing or any suspected adulterated sterile pharmaceuticals to the Department of Consumer Protection.
186 pharmaceuticals shall report any errors related to such dispensing or any suspected adulterated sterile pharmaceuticals to the Department of Consumer Protection.
(m) Notwithstanding the provisions of this section, (1) the addition of a flavoring agent in accordance with subsections (a) and (b) of section 20-617a shall be exempt from the requirements of United States Pharmacopeia, Chapter 795, Pharmaceutical Compounding – Nonsterile Preparations, and Chapter 800, Hazardous Drugs, as both may be amended from time to time, and (2) no sterile compounding pharmacy shall sell or transfer a sterile pharmaceutical directly to another person with actual knowledge that such other person intends to use the sterile pharmaceutical to execute a sentence of death imposedby a court.
(m) Notwithstanding the provisions of this section, (1) the addition of a flavoring agent in accordance with subsections (a) and (b) of section 20-617a shall be exempt from the requirements of United States Pharmacopeia, Chapter 795, Pharmaceutical Compounding – Nonsterile Preparations, and Chapter 800, Hazardous Drugs, as both may be amended from time to time, and (2) no sterile compounding pharmacy shall sell or transfer a sterile pharmaceutical directly to another person with actual knowledge that such other person intends to use the sterile pharmaceutical to execute a sentence of death imposedby LCO 19 of 20 Substitute Bill No.
(n) The Commissioner of Consumer Protection may adopt sHB5225 / File No.
5225 a court.
186 19 sHB5225 File No.
(n) The Commissioner of Consumer Protection may adopt regulations, in accordance with chapter 54, to implement the provisions of subsections (a) to (m), inclusive, of this section.
186 regulations, in accordance with chapter 54, to implement the provisions of subsections (a) to (m), inclusive, of this section.
5 October 1, 2026 20-593(c) Sec.
5 October 1, 2026 20-593(c) October 1, 2026 Sec.
6 October 1, 2026 20-613(d) Sec.
6 20-613(d) Sec.
9 June 15, 2026 20-633b(d) to (n) Statement of Legislative Commissioners:
9 June 15, 2026 20-633b(d) to (n) GL Joint Favorable Subst.
In Section 1(f) and (g), "Wholesalers and manufacturers" was changed to "[Wholesalers and manufacturers] Manufacturers and wholesalers" for consistency;
JUD Joint Favorable LCO 20 of 20
and in Section 6(d), "be construed to" was added for consistency with standard drafting conventions.
GL Joint Favorable Subst.
sHB5225 / File No.
186 20 sHB5225 File No.
186 The following Fiscal Impact Statement and Bill Analysis are prepared for the benefit of the members of the General Assembly, solely for purposes of information, summarization and explanation and do not represent the intent of the General Assembly or either chamber thereof for any purpose.
In general, fiscal impacts are based upon a variety of informational sources, including the analyst’s professional knowledge.
Whenever applicable, agency data is consulted as part of the analysis, however final products do not necessarily reflect an assessment from any specific department.
OFA Fiscal Note State Impact:
Agency Affected Fund-Effect FY 27 $ FY 28 $ Resources of the General Fund GF - Potential See Below See Below Revenue Gain Note:
GF=General Fund Municipal Impact:
None Explanation The bill prohibits manufacturing, selling, or dispensing a drug while knowing that the drug will be used to execute a death sentence and make certain violations subject to a civil penalty of up to $1,000 or a fine of up to $500 resulting in a potential revenue gain to the state to the extent violations occur.
The Out Years The annualized ongoing fiscal impact identified above would continue into the future subject to the number of violations.
sHB5225 / File No.
186 21 sHB5225 File No.
186 OLR Bill Analysis sHB 5225 AN ACT PROHIBITING CERTAIN LICENSEES AND REGISTRANTS FROM SELLING, DISPENSING, TRANSFERRING OR DELIVERING ANY DRUG OR DEVICE TO EXECUTE A COURT-IMPOSED SENTENCE OF DEATH.
SUMMARY This bill generally prohibits manufacturing, selling, or dispensing a drug while knowing that the person receiving it intends to use it to execute a court-imposed death sentence.
The bill also authorizes the Department of Consumer Protection (DCP) or the Commission of Pharmacy, depending on the credential, to take various actions when a credential holder takes certain actions involving a drug that the holder knows will be used by someone to execute a court-imposed death sentence.
EFFECTIVE DATE:
October 1, 2026, except the prohibited actions related to manufacturers, wholesalers, sterile compounding pharmacies, and certain people take effect June 15, 2026.
§§ 1-3 — DRUG MANUFACTURERS AND WHOLESALERS By law, drug manufacturers and wholesalers (distributors) must register with DCP.
Currently, a retail pharmacy that supplies an emergency stock of certain drugs to a prison medical director is not a wholesaler or distributor and does not have to register.
The bill requires registration when the prison has actual knowledge that a noncontrolled drug or controlled substance will be used to execute a court-imposed death sentence.
(The bill does not specify how to attribute this knowledge to the prison.) By law, the DCP commissioner can deny a registration certificate if issuing one would be inconsistent with the public interest.
The law sets sHB5225 / File No.
186 22 sHB5225 File No.
186 out a number of factors the commissioner must consider in making this determination, including certain convictions or regulatory actions, the applicant’s past experience and regulatory compliance, and having adequate controls and security.
The bill also requires the commissioner to consider if the applicant manufactured, sold, or dispensed a drug or device actually knowing that the person purchasing or receiving it directly fromthe applicant intended to use it to execute a court-imposed death sentence.
The law specifies a number of reasons that are sufficient for the commissioner to suspend, revoke, or refuse to renew a registration, reprimand a registrant, or place a registrant on probation, such as criminal convictions related to drugs, providing false information, lack of adequate controls, or violating state or federal drug laws.
The bill adds to this list manufacturing, selling, or dispensing a drug or device when actually knowing that the person purchasing or receiving it directly from the registrant intends to use it to execute a court-imposed death sentence.
The bill requires an applicant or registrant seeking renewal to attest to the commissioner in a signed written statement that the applicant or registrant will not manufacture, sell, or dispense a drug or device when actually knowing that the person purchasing or receiving it directly from the applicant or registrant intends to use it to execute a court- imposed death sentence.
The DCP commissioner must set the form and manner for this statement.
The law requires a manufacturer or wholesaler to obtain a DCP license to sell and dispense controlled substances.
The bill prohibits a licensed manufacturer or wholesaler from selling or dispensing a controlled drug directly to another person while actually knowing that the person intends to use it to execute a court-imposed death sentence.
§ 3 — CERTAIN INDIVIDUALS Current law allows the person in charge of a hospital, college, scientific institution, or laboratory, an employee of this or another state sHB5225 / File No.
186 23 sHB5225 File No.
186 or their political subdivisions, or a proper officer of a ship or aircraft who obtains a controlled substance to administer it within the scope of his or her employment or duty and only for scientific or medicinal purposes or research or analysis.
The bill prohibits these individuals from obtaining, dispensing, or using a controlled drug to execute a court-imposed death sentence.
§§ 4 & 5 — PHARMACISTS By law, the Commission of Pharmacy can (1) refuse to issue a temporary permit to practice pharmacy;
(2) refuse to issue or renew a license to practice pharmacy or operate a pharmacy or registration of a pharmacy intern or technician;
(3) revoke, suspend, or place conditions on any of these credentials;
(4) reprimand or place on probation a credential holder;
or (5) assess a civil penalty of up to $1,000 per violation for numerous grounds.
The bill adds to the permissible grounds for these actions that while holding the credential, the person dispensed or distributed a drug or device directly to someone while actually knowing that the person intended to use it to execute a court- imposed death sentence.
The bill also prohibits the commission from renewing a pharmacist license if within the calendar year before the application the person dispensed or distributed a drug or device directly to someone while actually knowing that the person intended to use it to execute a court- imposed death sentence.
§§ 6 & 7 — PRESCRIPTIONS The bill prohibits a prescribing practitioner (a person licensed by any state or U.S.
jurisdiction who is authorized to issue a prescription within the scope of the person’s practice) from dispensing or transferring a drug or device directly to someone while actually knowing that the person intends to use it to execute a court-imposed death sentence.
The bill makes any request for a controlled substance to execute a court-imposed death sentence an invalid prescription and considers it outside the context of a valid practitioner-patient relationship.
sHB5225 / File No.
186 24 sHB5225 File No.
186 § 8 — NONRESIDENT PHARMACY REGISTRATION CERTIFICATE Current law allows the Commission of Pharmacy to deny, revoke, or suspend a nonresident pharmacy’s registration certificate for failing to comply with state or federal laws or regulations, delivering an adulterated or misbranded legend drug or device, or disciplinary actions taken against the pharmacy by any state or federal agency.
The bill adds as an additional ground for these actions by the commission that the pharmacy delivered a legend drug or device directly to someone while actually knowing that the person intends to use it to execute a court-imposed death sentence.
§ 9 — STERILE COMPOUNDING PHARMACIES The bill prohibits a sterile compounding pharmacy from providing, selling, or transferring a sterile pharmaceutical directly to someone while actually knowing that the person intends to use it to execute a court-imposed death sentence.
COMMITTEE ACTION General Law Committee Joint Favorable Substitute Yea 13 Nay 7 (03/11/2026) sHB5225 / File No.
186 25
⬇ Download PDF
View plain text versions (4)

How this bill changes current law

1 change Share ↗

AI-generated reading aid from the bill's amendatory text — verify against the official bill.

The bill prohibits certain licensees and registrants from selling, dispensing, transferring, or delivering any drug or device that is intended for use in executing a sentence of death.

  • Section 21a-70

    any drug or device with actual knowledge that the person purchasing or receiving such drug or device directly from the applicant intends to use such drug or device to execute a sentence of death; → any drug or device to execute a sentence of death;

    This change explicitly prohibits the sale, dispensing, transferring, or delivering of any drug or device intended for use in capital punishment.

Action History

  1. SENATE CALENDAR NUMBER 448

  2. FAV. RPT., TAB. FOR CAL., SEN.

  3. HOUSE PASSED

  4. TABLED FOR HOUSE CALENDAR

  5. NO NEW FILE BY COMM. ON Judiciary

  6. RPTD. OUT OF LCO

  7. FILED WITH LCO

  8. Joint Favorable

  9. REF. BY HOUSE TO COMMITTEE ON Judiciary

  10. FILE NO. 186

  11. HOUSE CALENDAR NUMBER 152

  12. FAV. RPT., TABLED FOR HOUSE CALENDAR

  13. RPTD. OUT OF LCO

  14. REFERRED TO Office of Legislative Research AND Office of Fiscal Analysis 03/25/26

  15. FILED WITH LCO

  16. Joint Favorable Substitute

  17. PUBLIC HEARING 0223

  18. REF. TO JOINT COMM. ON General Law

Sponsors

Sponsorship breakdown

Export CSV (upgrade) →

8 sponsors · 0 co-sponsors · 179 not signed on

Sponsors (8)

Co-sponsors (0)

None.

Not signed on (179)

179 members have not signed on to this bill.

Show all 179 →

"Not signed on" means a member has not sponsored or co-sponsored this bill — it does not imply opposition. Members flagged Voted No have a recorded No vote on this bill.

Whip count is in markup. Polling the chamber and every recorded vote this session. Only the first open is slow. It’s instant for you after this. Calling the roll · Tallying · Engrossing

Subjects

public-safety civil-rights health-insurance
Cross-referencing the record. Reading this bill against every other bill in the corpus by meaning, not keywords. Only the first open is slow. It’s instant for you after this. Matching · Ranking · Engrossing

Frequently asked questions

Who sponsors HB 5225?
HB 5225 is sponsored by Antonio Felipe (Democratic), Patricia A. Dillon (Democratic), Nick Gauthier (Democratic), Ceci Maher (Democratic), Martha Marx (Democratic), Gary A. Winfield (Democratic), Nicholas Menapace (Democratic), and Saud Anwar (Democratic).
What is the current status of HB 5225?
This bill has passed the House. Introduced February 18, 2026. It now moves to the second chamber.
Where can I track HB 5225?
Track HB 5225 free on One Click Politics — get push/email alerts when it moves.

Make your voice heard on HB 5225

Find the representatives who decide this bill and tell them where you stand — for yourself, or mobilize your whole list in one click with One Click Politics advocacy software.

Find my representatives → Run a campaign

Stay ahead of HB 5225

Last checked for changes 3 months ago · updated continuously

One Click Politics tracks every bill in Congress and all 50 states.

Track this bill →